Literature DB >> 21994214

A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients.

A G Dumont1, L Rink2, A K Godwin3, M Miettinen4, H Joensuu5, J R Strosberg6, A Gronchi7, C L Corless8, D Goldstein9, B P Rubin10, R G Maki11, A J Lazar12, D Lev13, J C Trent14, M von Mehren2.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) and desmoid tumors (DTs) are two rare mesenchymal tumor. Anecdotal reports of individuals with both diseases led us to make the hypothesis that the association is a nonrandom event as the probability would be extremely low to observe such cases if they were independent events. PATIENTS AND METHODS: We evaluated the existence of patients with GIST and DT in a large multicenter cohort at 10 institutions in the United States, Australia and Europe. Data on gender, age at diagnosis, KIT, PDGFRA, CTNNB1 mutation status and follow-up time after diagnosis were collected.
RESULTS: We identified 28 patients diagnosed with both tumors. DT was diagnosed after GIST in 75% of patients and concomitantly in 21%. In only one case (4%), GIST was diagnosed after DT. KIT or PDGFRA mutations were detected in 12 of 14 GIST, 9 in KIT exon 11, 2 in KIT exon 9 and 1 in PDGFRA.
CONCLUSION: A statistical analysis of these 28 cases suggests a nonrandom association between GIST and DT. Further studies may be able to elucidate the underlying biology responsible for this association.

Entities:  

Mesh:

Year:  2011        PMID: 21994214      PMCID: PMC3493136          DOI: 10.1093/annonc/mdr442

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  46 in total

1.  Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor).

Authors:  S Tejpar; F Nollet; C Li; J S Wunder; G Michils; P dal Cin; E Van Cutsem; B Bapat; F van Roy; J J Cassiman; B A Alman
Journal:  Oncogene       Date:  1999-11-11       Impact factor: 9.867

2.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors:  Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal:  Eur J Cancer       Date:  2006-04-18       Impact factor: 9.162

3.  Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.

Authors:  R K Pandurengan; A G Dumont; D M Araujo; J A Ludwig; V Ravi; S Patel; J Garber; R S Benjamin; S S Strom; J C Trent
Journal:  Ann Oncol       Date:  2010-03-26       Impact factor: 32.976

Review 4.  Desmoids in familial adenomatous polyposis.

Authors:  S K Clark; R K Phillips
Journal:  Br J Surg       Date:  1996-11       Impact factor: 6.939

5.  The desmoid tumor. Not a benign disease.

Authors:  M C Posner; M H Shiu; J L Newsome; S I Hajdu; J J Gaynor; M F Brennan
Journal:  Arch Surg       Date:  1989-02

6.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

7.  Gastric stromal tumors. Reappraisal of histogenesis.

Authors:  M T Mazur; H B Clark
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

8.  Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Grace C Wong; Tianhua Guo; Robert G Maki; Samuel Singer; Ronald P Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

9.  KIT regulates tyrosine phosphorylation and nuclear localization of beta-catenin in mast cell leukemia.

Authors:  Tomohiro Kajiguchi; Sunmin Lee; Min-Jung Lee; Jane B Trepel; Len Neckers
Journal:  Leuk Res       Date:  2007-10-18       Impact factor: 3.156

Review 10.  Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Pol J Pathol       Date:  2003       Impact factor: 1.072

View more
  15 in total

1.  Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.

Authors:  James D Murphy; Grace L Ma; Joel M Baumgartner; Lisa Madlensky; Adam M Burgoyne; Chih-Min Tang; Maria Elena Martinez; Jason K Sicklick
Journal:  Cancer       Date:  2015-04-30       Impact factor: 6.860

Review 2.  Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature.

Authors:  Jaclyn Frances Hechtman; Ronald DeMatteo; Khedoudja Nafa; Ping Chi; Maria E Arcila; Snjezana Dogan; Alifya Oultache; Wen Chen; Meera Hameed
Journal:  Ann Surg Oncol       Date:  2015-01-07       Impact factor: 5.344

3.  Desmoid tumor mimicking GIST recurrence.

Authors:  Nina Nandy; Wendy Garvin; Thalia L Mesologites; Joel S Silver; Constantin A Dasanu
Journal:  J Gastrointest Cancer       Date:  2014-12

4.  Gastrointestinal stromal tumors of the esophagus: evaluation of a pooled case series regarding clinicopathological features and clinical outcome.

Authors:  Simon Lott; Michael Schmieder; Benjamin Mayer; Doris Henne-Bruns; Uwe Knippschild; Abbas Agaimy; Matthias Schwab; Klaus Kramer
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

5.  Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.

Authors:  Cristina R Antonescu; Salvatore Romeo; Lei Zhang; Khedoudja Nafa; Jason L Hornick; Gunnlaugur Petur Nielsen; Mari Mino-Kenudson; Hsuan-Ying Huang; Juan-Miguel Mosquera; Paolo A Dei Tos; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

6.  Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report.

Authors:  Margherita Nannini; Maria Abbondanza Pantaleo; Fausto Catena; Stefania Romano; Salvatore Tondo; Maria Giulia Pirini; Cristian Lolli; Alessandra Maleddu; Anna Mandrioli; Lidia Gatto; Maristella Saponara; Maria Caterina Pallotti; Angelo Paolo Dei Tos; Antonio Daniele Pinna; Guido Biasco
Journal:  Int J Surg Case Rep       Date:  2012-09-19

7.  Subsequent intra-abdominal fibromatosis mimicking recurrent gastrointestinal stromal tumor.

Authors:  Dongxian Jiang; Deming He; Yingyong Hou; Weiqi Lu; Yuan Shi; Qin Hu; Shaohua Lu; Chen Xu; Yalan Liu; Ju Liu; Yunshan Tan; Xiongzeng Zhu
Journal:  Diagn Pathol       Date:  2013-07-31       Impact factor: 2.644

8.  Mesenteric fibromatosis after resection for gastrointestinal stromal tumor of stomach: A case report.

Authors:  Yiming Chu; Qingqu Guo; Dan Wu
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Subsequent Development of Desmoid Tumor after a Resected Gastrointestinal Stromal Tumor.

Authors:  Areen Abdulelah Murshid; Hatim Q Al-Maghraby
Journal:  Case Rep Pathol       Date:  2018-05-02

Review 10.  Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review.

Authors:  Antonia Dimitrakopoulou-Strauss; Ulrich Ronellenfitsch; Caixia Cheng; Leyun Pan; Christos Sachpekidis; Peter Hohenberger; Thomas Henzler
Journal:  Clin Transl Imaging       Date:  2017-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.